The GLP-1 family of peptides is a set of incretin-receptor agonists that has transformed the pharmacological treatment of type 2 diabetes and obesity over the past two decades. The family is best understood not as a single drug class but as a layered architecture of receptor-engagement profiles: selective GLP-1 receptor agonists (exemplar: semaglutide), dual GIP and GLP-1 receptor agonists (exemplar: tirzepatide), triple GIP/GLP-1/glucagon receptor agonists (exemplar: retatrutide, in Phase 3 development), and oral non-peptide GLP-1 receptor agonists (exemplar: orforglipron, FDA-approved April 2026). Each layer adds an additional pharmacological dimension to the previous one.
This post is the methodological complement to the Beginner’s Guide to Research Peptides, which covers regulatory status across the catalog at a high level. This post focuses on the underlying biology: the incretin axis, the mechanistic differences between selective, dual, and triple agonism, the structure-activity logic that produces those differences, and the shared side-effect profile that defines the class as a whole. Researchers should treat each compound’s published clinical literature on its own terms; the family-level framing here is mechanistic, not clinical-equivalence.
Important Note on the Evidence Base
Important note on the evidence base: The GLP-1 family includes compounds with completed Phase 3 trial programs and FDA approval (semaglutide, tirzepatide, orforglipron), compounds in active Phase 3 development (retatrutide), and earlier-stage candidates not covered here. Phase 3 efficacy and safety data from one compound do not transfer to another; class-level statements in this post describe mechanism and the shared side-effect profile, not equivalent clinical effects.
What Is GLP-1?
Glucagon-like peptide-1 (GLP-1) is an endogenous 30-amino-acid incretin hormone secreted by enteroendocrine L-cells in the distal small intestine and colon in response to oral nutrient intake. It is cleaved from the larger proglucagon precursor by the prohormone convertase PC1/3. Native GLP-1 circulates in two principal active forms (GLP-1[7-37] and GLP-1[7-36] amide) and acts through the GLP-1 receptor, a class B G-protein-coupled receptor expressed in pancreatic beta cells, pancreatic alpha cells, gastric parietal cells, gastric smooth muscle, vagal afferents, and several central-nervous-system regions including the area postrema, hypothalamus, and brainstem nuclei.
Native GLP-1 has a circulatory half-life of approximately two minutes. The short half-life reflects rapid enzymatic inactivation by dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal His-Ala dipeptide and converts active GLP-1 to an inactive metabolite. This pharmacokinetic constraint has shaped the entire pharmacological strategy for engaging the GLP-1 receptor: every approved GLP-1 receptor agonist incorporates structural modifications that resist DPP-4 inactivation, extend the circulatory half-life, and enable practical administration intervals.
The physiological actions of GLP-1 in response to a meal include glucose-dependent stimulation of insulin secretion from pancreatic beta cells, suppression of inappropriate glucagon release from pancreatic alpha cells, slowing of gastric emptying, and central-nervous-system effects on appetite and satiety. The glucose-dependence of the insulinotropic effect is mechanistically important: GLP-1 does not stimulate insulin release at low glucose, which is why GLP-1-class agents have a low intrinsic risk of hypoglycemia in monotherapy.
The Incretin Axis: GIP and GLP-1
GLP-1 is one of two incretin hormones; the other is glucose-dependent insulinotropic polypeptide (GIP), a 42-amino-acid hormone secreted by enteroendocrine K-cells in the duodenum and proximal jejunum. The two hormones together produce the incretin effect — the observation, first quantified in the 1960s, that an oral glucose load produces a substantially greater insulin response than an intravenous glucose load matched for plasma glucose. The incretin effect is reduced in type 2 diabetes, and pharmacological restoration of incretin signaling has been a central therapeutic strategy in the disease for two decades.
The two incretin receptors are pharmacologically distinct. The GLP-1 receptor’s signaling cascade is dominated by Gs-coupled adenylyl cyclase activation, with downstream cyclic AMP and protein kinase A signaling driving glucose-dependent insulin secretion, satiety signaling, and gastric emptying delay. The GIP receptor is also Gs-coupled but additionally engages adipocyte and central-nervous-system pathways that are distinct from the GLP-1 receptor’s. Native GIP secretion is preserved in type 2 diabetes, but GIP receptor signaling is attenuated — one of several reasons the pharmacological logic of combined GIP/GLP-1 agonism (the dual-incretin strategy) is biologically motivated rather than empirical.
A third hormone often referenced alongside the incretins is glucagon, which is secreted by pancreatic alpha cells and acts at the glucagon receptor to raise blood glucose — physiologically opposing GLP-1’s action. The triple-agonist strategy (engaging GIP, GLP-1, and glucagon receptors with a single molecule) appears, at first, to combine receptor agonisms with opposing metabolic effects. The mechanistic rationale is that glucagon receptor agonism increases energy expenditure and reduces hepatic fat content through direct hepatic and adipose effects, while the GLP-1 component suppresses excess glucagon-driven hepatic glucose output and the GIP component augments insulin secretion — producing net glycemic improvement and weight reduction beyond what selective GLP-1 agonism alone can achieve. The clinical hypothesis underlying triple agonism is that the three signals integrate at the level of whole-body energy balance rather than at the level of any single tissue.
Selective GLP-1 Receptor Agonists — Semaglutide as Exemplar
Semaglutide is a synthetic 31-amino-acid peptide analog of native human GLP-1, modified at two positions to resist DPP-4 cleavage and conjugated to a fatty diacid moiety via a hydrophilic linker. The fatty acid attachment promotes reversible binding to serum albumin, which both protects the peptide from renal clearance and extends the circulatory half-life to approximately one week — enabling once-weekly subcutaneous administration. The structure-activity logic of semaglutide is a refinement of the earlier-generation GLP-1 agonist exenatide (a synthetic version of exendin-4, a peptide isolated from Gila monster venom) and is closely related to the longer-acting analog liraglutide.
The Phase 3 STEP program established semaglutide’s efficacy profile in chronic weight management. In the 68-week STEP-1 trial, adults with overweight or obesity (without diabetes) who received once-weekly subcutaneous semaglutide 2.4 mg achieved a mean body-weight reduction of 14.9%, compared with 2.4% in the placebo group, with 86% of treated participants attaining at least 5% weight loss [1]. The corresponding Phase 3 program in type 2 diabetes (SUSTAIN) and the cardiovascular outcomes trial (SUSTAIN-6 and SELECT) extended the evidence base into glycemic and cardiovascular endpoints. Semaglutide is FDA-approved for type 2 diabetes (2017) and chronic weight management (2021), with corresponding EMA approval in both indications.
Semaglutide’s clinical profile defines the selective GLP-1 receptor agonist class: substantial weight reduction (10–15% in chronic-weight-management trials), HbA1c reductions in the 1.5–2.0% range in diabetes, glucose-dependent insulin secretion with low intrinsic hypoglycemia risk, and a amount-related gastrointestinal adverse-event profile that is the dominant tolerability constraint in clinical use.
Dual Agonists — Tirzepatide (GIP + GLP-1)
Tirzepatide (development code LY3298176) is a synthetic, once-weekly, fatty-acid-modified 39-amino-acid peptide that functions as a dual GIP and GLP-1 receptor agonist. It is the first agent of its dual-incretin class to reach regulatory approval. Coskun and colleagues at Eli Lilly characterized tirzepatide’s pharmacological profile across cell-line signaling assays, in vivo studies in obese mice, and human studies in type 2 diabetes [2]: the compound activates both GIP and GLP-1 receptor signaling in vitro, lowers blood glucose in mice through actions on both incretin receptors, and produces greater weight loss in healthy humans than the selective GLP-1 receptor agonist dulaglutide.
The compound is best understood as an “imbalanced and biased” dual agonist. At clinically efficacious amounts, the calculated receptor occupancy favors the GIP receptor, while at the GLP-1 receptor the compound shows signaling bias toward cyclic AMP with reduced receptor desensitization compared with native GLP-1. This pharmacological profile may help explain the magnitude of weight loss reported in the Phase 3 SURMOUNT and SURPASS programs relative to selective GLP-1 receptor agonists. The fatty-acid modification confers reversible binding to serum albumin and a circulatory half-life of approximately five days, enabling once-weekly subcutaneous administration with the same titration logic as semaglutide.
In the 72-week SURMOUNT-1 obesity trial, adults without type 2 diabetes who received once-weekly subcutaneous tirzepatide achieved mean body-weight reductions of 15.0%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg amounts respectively, compared with 3.1% in the placebo group [3]. In the head-to-head SURPASS-2 trial in adults with type 2 diabetes, tirzepatide was reported as noninferior and superior to semaglutide 1 mg with respect to mean change in glycated hemoglobin [4]. Tirzepatide is FDA-approved for type 2 diabetes (2022) and chronic weight management (2023), with corresponding EMA approval in both indications.
Triple Agonists — Retatrutide (GIP + GLP-1 + Glucagon)
Retatrutide (development code LY3437943) is a synthetic, fatty-acid-modified peptide that functions as a triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. Cell-culture characterization indicates that retatrutide is less potent than endogenous ligands at the human glucagon and GLP-1 receptors (0.3 and 0.4 times the activity of native ligand, respectively) and more potent at the human GIP receptor (by a factor of approximately 8.9). The compound is single-chain, conjugated to a fatty diacid moiety, with a half-life of approximately six days — supporting once-weekly subcutaneous administration with the same broad administration architecture as tirzepatide and semaglutide.
The TRIUMPH Phase 3 program in obesity and obesity-related conditions is ongoing. Published Phase 2 data have established the clinical profile underlying the Phase 3 design. In the 48-week Phase 2 obesity trial published by Jastreboff and colleagues, adults with obesity (or overweight with at least one weight-related condition) randomized to retatrutide achieved mean body-weight reductions of 22.8% and 24.2% at the 8 mg and 12 mg amounts respectively, compared with 2.1% in the placebo group [5]. At the 12 mg amount, 83% of participants achieved at least 15% weight loss. The most common adverse events were gastrointestinal, amount-related, mostly mild to moderate, and partially mitigated by a lower 2 mg starting amount. Concentration-dependent increases in heart rate peaked at 24 weeks and declined thereafter — a profile not observed with the selective GLP-1 or dual GIP/GLP-1 agonist programs and consistent with the glucagon-receptor component’s energy-expenditure effect.
Retatrutide has not received regulatory approval in any jurisdiction. Phase 3 trial readouts continue through 2026 and beyond.
Oral Non-Peptide GLP-1 Receptor Agonist — Orforglipron
Orforglipron (development code LY3502970) is a once-daily, oral, small-molecule, non-peptide GLP-1 receptor agonist. Its categorical distinction from the other compounds in this post is structural: orforglipron is not a peptide, it is a small organic molecule with a defined non-peptide chemical scaffold designed for oral bioavailability. The compound binds the GLP-1 receptor at an allosteric site distinct from where native GLP-1 binds and produces functional agonist signaling through a different binding mode than native or peptide-analog ligands.
The pharmacokinetic implications are substantial. Orforglipron does not require fatty-acid conjugation or albumin-binding for half-life extension; its oral bioavailability is sufficient to support once-daily administration without the food-and-water restrictions that constrain orally administered peptide GLP-1 agonists. The mechanistic profile is that of a selective GLP-1 receptor agonist (not dual or triple), with no GIP or glucagon-receptor engagement.
The Phase 3 ATTAIN program established orforglipron’s clinical profile in obesity. In the 72-week ATTAIN-1 trial, adults with obesity or overweight with a weight-related medical problem (without diabetes) randomized to once-daily orforglipron at 6 mg, 12 mg, or 36 mg achieved mean body-weight reductions of 7.5%, 8.4%, and 11.2% respectively, compared with 2.1% in the placebo group [6]. The corresponding ATTAIN-2 trial extended the program to adults with obesity or overweight and type 2 diabetes, with statistically superior body-weight reduction compared with placebo. The adverse-event profile was consistent with the GLP-1 receptor agonist class. Orforglipron received FDA approval for chronic weight management on April 1, 2026.
The clinical positioning of orforglipron within the GLP-1 family is the once-daily oral option. The 11.2% mean weight reduction at the 36 mg amount is lower than that reported for once-weekly subcutaneous tirzepatide or semaglutide at their respective maintenance amounts; the trade-off is oral administration and the absence of subcutaneous injection requirements. Whether the lower magnitude of weight reduction reflects the selective (rather than dual) receptor profile, the oral pharmacokinetic ceiling, or both is an open question in the literature.
Side-Effect Class Profile — GI Dominant, Amount-Related, Mitigated by Titration
The GLP-1 family shares a recognizable side-effect profile that is among the most thoroughly characterized in modern endocrine pharmacology. The dominant adverse events across selective, dual, triple, and oral-non-peptide subclasses are gastrointestinal: nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal discomfort. These events are amount-related (more frequent at higher amounts), most pronounced during escalating-amount, attenuate over time at the maintenance amount, and are largely mitigated by a stepwise titration schedule that begins below the target therapeutic amount and increases at 4-week intervals.
Other class-level signals. Beyond gastrointestinal events, the class shares a tendency to amount-related increases in heart rate (most prominent with the triple agonist retatrutide, smallest with selective GLP-1 agonists), reductions in systolic blood pressure (favorable, but relevant to overall cardiovascular signal interpretation), and rare reports of acute pancreatitis (low absolute risk but consistently monitored across the trial programs). The cardiovascular outcomes data for semaglutide (SELECT trial) and tirzepatide (SURPASS-CVOT) have supported the broader cardiovascular safety profile of the class in their respective approved populations. Cardiovascular outcomes data for retatrutide and orforglipron are emerging.
For research-protocol design that engages any of the compounds in this family, the gastrointestinal adverse-event profile and the importance of titration timing are the dominant practical constraints. Cardiovascular and pancreatic monitoring follow the published trial protocols.
Available Research Formats
Omnix Peptides supplies semaglutide, tirzepatide, retatrutide, and orforglipron as research-grade material in vial format (lyophilized powder for reconstitution). The vial is the canonical research format used in the published clinical literature for the injectable peptides in this family. Each lot ships with a batch-specific Certificate of Analysis and is supplied under the For Research Use Only standard. See the individual compound hubs for current format availability: semaglutide, tirzepatide, retatrutide, and orforglipron. All four compounds are classified under the Metabolic & Weight research category.
Frequently Asked Questions
What is the difference between a selective GLP-1 agonist and a dual GIP/GLP-1 agonist?
A selective GLP-1 receptor agonist (such as semaglutide) engages only the GLP-1 receptor. A dual GIP and GLP-1 receptor agonist (such as tirzepatide) engages both incretin receptors simultaneously. In the head-to-head SURPASS-2 trial in adults with type 2 diabetes, tirzepatide produced greater reductions in HbA1c and body weight than once-weekly semaglutide 1 mg; the dual-receptor profile is the leading mechanistic hypothesis for the larger effect size.
What is a triple agonist and how does retatrutide differ from tirzepatide?
A triple agonist engages three receptors simultaneously. Retatrutide is a triple agonist of the GIP, GLP-1, and glucagon receptors. Tirzepatide is a dual agonist of the GIP and GLP-1 receptors only. The glucagon receptor component of retatrutide is the mechanistic distinction; it contributes to energy expenditure and hepatic fat reduction through pathways not engaged by selective or dual incretin agonists. Retatrutide is in Phase 3 development under the TRIUMPH program and has not received regulatory approval.
Why is orforglipron oral when the other GLP-1 family compounds are injected?
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. Because it is not a peptide, it is not subject to the gastrointestinal-protease degradation that limits oral bioavailability of peptide GLP-1 agonists. Orforglipron binds the GLP-1 receptor at an allosteric site different from where native GLP-1 binds, with a different binding mode than peptide analogs. It is administered once daily by mouth and received FDA approval for chronic weight management in April 2026.
Why do all GLP-1 family compounds use stepwise concentration-titration?
Every approved or Phase 3 compound in the GLP-1 family is administered using a stepwise escalating-amount schedule in published clinical protocols. Participants begin at a sub-therapeutic amount and titrate upward at 4-week intervals to the target maintenance amount. The titration is designed to mitigate the gastrointestinal adverse events (nausea, vomiting, diarrhea, decreased appetite) that are characteristic of incretin-class signaling at the area postrema and hypothalamic appetite-regulating regions. These events are most pronounced during early escalating-amount and attenuate over time at the maintenance amount as the relevant central pathways adapt.
How does GLP-1 act on appetite and satiety?
Native GLP-1 produces central appetite and satiety signaling through GLP-1 receptors expressed in the area postrema, hypothalamus, and brainstem nuclei. Activation of these receptors reduces appetite, increases satiety after meals, and contributes to the weight-loss effects observed with GLP-1 receptor agonist therapy in clinical trials. The same central GLP-1 receptor pathways are also responsible for the nausea and decreased-appetite adverse events characteristic of the class, which is why those events are most prominent during escalating-amount.
Is the cardiovascular safety of GLP-1 receptor agonists established?
Cardiovascular outcomes trials for semaglutide (SELECT in obesity, SUSTAIN-6 in diabetes) and tirzepatide (SURPASS-CVOT in diabetes) have reported favorable cardiovascular outcomes in the approved populations for those compounds. Cardiovascular outcomes data for retatrutide and orforglipron are emerging and continue to develop. Class-level cardiovascular safety conclusions are appropriate for the approved population in each compound’s individual cardiovascular outcomes trial; cross-compound extrapolation should be cautious.
References
- Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 · PubMed: 33567185
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009 · PubMed: 30473097
- Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 · PubMed: 35658024
- Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519 · PubMed: 34170647
- Jastreboff AM, Kaplan LM, Frías JP, et al; Retatrutide Phase 2 Obesity Trial Investigators. Triple–hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972 · PubMed: 37366315
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774 · PubMed: VERIFY-PMID
- Horn DB, Ryan DH, Giljanovic Kis S, et al; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a Phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025. doi:10.1016/S0140-6736(25)02165-8 · PubMed: VERIFY-PMID
Citations 1–5 are verified-load-bearing references anchoring the structural argument of this guide. Citations 6–7 have verified DOIs; PubMed IDs are flagged for the editorial QC pass (papers were published after standard PMID indexing windows in some PubMed mirrors).
For Research Use Only. The products described on this page are sold strictly for in vitro laboratory research and are not intended for human or animal consumption, diagnostic use, or therapeutic use. The published research summarized above is provided as scientific reference material; where compounds described in this post have approved drug products in defined indications, those approved drug products are available only by prescription from a licensed healthcare provider and are distinct from the research-grade material supplied here. Nothing on this page constitutes medical advice, a therapeutic claim, or a recommendation for any use outside of a properly resourced and ethically reviewed research setting.